The DOI matches its Crossref record.
Detection and Characterization of Focal Liver Lesions: A Japanese Phase III, Multicenter Comparison Between Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging and Contrast-Enhanced Computed Tomography Predominantly in Patients With Hepatocellular Carcinoma and Chronic Liver Disease
Abstract
OBJECTIVES: To prospectively evaluate the safety and efficacy of combined unenhanced and gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance (MR) imaging compared with unenhanced MR imaging and triphasic contrast-enhanced spiral computed tomography (CT) for the detection and characterization of focal liver lesions. MATERIALS AND METHODS: The study was reviewed and approved by the institutional review board at each of the 15 centers involved in the study, and informed written consent was given by all patients. In total, 178 patients with suspected focal hepatic lesions (based, in most patients, on CT, tumor marker and ultrasound examinations) underwent combined MR imaging with a single, rapid injection of Gd-EOB-DTPA 0.025 mmol/kg, including T1-weighted dynamic and delayed MR images 20 to 40 minutes postinjection. Triphasic contrast-enhanced CT, the comparator examination, was performed within 4 weeks of MR imaging. Standard of references (SOR) were resection histopathology and intraoperative ultrasonography, or combined CT during arterial portography and CT hepatic arteriography; in cases where, although the major lesions were treated, some lesion(s) were not treated, follow-up superparamagnetic iron oxide-enhanced MR imaging was additionally performed. All images were assessed for differences in lesion detection and characterization (specific lesion type) by on-site readers and 3, blinded (off-site) reviewers. All adverse events (AEs) occurring within 72 hours after Gd-EOB-DTPA administration were reported. RESULTS: Overall, 9.6% of patients who received Gd-EOB-DTPA reported 21 drug-related AEs. A total of 151 patients were included in the efficacy analysis. Combined MR imaging showed statistically higher sensitivity in lesion detection (67.5%-79.5%) than unenhanced MR imaging (46.5%-59.1%; P < 0.05 for all). Combined MR imaging also showed higher sensitivity in lesion detection than CT (61.1%-73.0%), with the results being statistically significant (P < 0.05) for on-site readers and 2 of 3 blinded readers. Higher sensitivity in lesion detection with combined MR imaging compared with CT was also clearly demonstrated in the following subgroups: lesions with a diameter <or=20 mm (lesions <or=10 mm: 38.0%-55.4% vs. 26.1%-47.3%, respectively; lesions 10-20 mm: 71.1%-87.3% vs. 65.7%-78.4%, respectively); in cirrhotic patients (64.5%-75.4% vs. 54.5%-70.3%, respectively); and in patients with hepatocellular carcinoma (66.6%-78.6% vs. 59.1%-71.6%, respectively). Combined MR imaging demonstrated a higher proportion of correctly characterized lesions (50.5%-72.1%) than unenhanced MR imaging (30.2%-50.0%; P < 0.05 for all), whereas there were no significant differences compared with CT (49.0%-68.1%), except for one blinded reader (P < 0.05). CONCLUSION: In this study, hepatocyte-specific Gd-EOB-DTPA was shown to be safe and to improve the detection and characterization of focal hepatic lesions compared with unenhanced MR imaging. When compared with spiral CT, Gd-EOB-DTPA enhanced MRI seems to be beneficial especially for the detection for smaller lesions or hepatocellular carcinoma underlying cirrhotic liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Mi, P., Kokuryo, D., Cabral, H., Wu, H., Terada, Y., Saga, T., Aoki, I., Nishiyama, N., & Kataoka, K. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.72 · Cited by 512
Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis
Roberts, L. R., Sirlin, C. B., Zaiem, F., Almasri, J., Prokop, L. J., Heimbach, J. K., Murad, M. H., & Mohammed, K. (2018) · Hepatology · doi:10.1002/hep.29487 · Cited by 497
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Metadata
- Authors
- Ichikawa, T., Saito, K., Yoshioka, N., Tanimoto, A., Gokan, T., Takehara, Y., Kamura, T., Gabata, T., Murakami, T., Ito, K., Hirohashi, S., Nishie, A., Saito, Y., Onaya, H., Kuwatsuru, R., Morimoto, A., Ueda, K., Kurauchi, M., & Breuer, J.
- Venue
- Investigative Radiology
- Published
- 2010-03
- Volume
- 45
- Issue
- 3
- Pages
- 133-141
- ISSN
- 0020-9996 (ISSN-L)
- OpenAlex
- W2133557716
- Cited by
- 234
- References
- 0
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detection and Characterization of Focal Liver Lesions: A Japanese Phase III, Multicenter Comparison Between Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging and Contrast-Enhanced Computed Tomography Predominantly in Patients With Hepatocellular Carcinoma and Chronic Liver Disease. https://app.cochat.ai/papers/10.1097/rli.0b013e3181caea5b
- The paper
- Ichikawa, T., Saito, K., Yoshioka, N., Tanimoto, A., Gokan, T., Takehara, Y., Kamura, T., Gabata, T., Murakami, T., Ito, K., Hirohashi, S., Nishie, A., Saito, Y., Onaya, H., Kuwatsuru, R., Morimoto, A., Ueda, K., Kurauchi, M., & Breuer, J. (2010). Detection and Characterization of Focal Liver Lesions: A Japanese Phase III, Multicenter Comparison Between Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging and Contrast-Enhanced Computed Tomography Predominantly in Patients With Hepatocellular Carcinoma and Chronic Liver Disease. Investigative Radiology. https://doi.org/10.1097/rli.0b013e3181caea5b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.